Dermatologic surgery opioid prescribing recommendations in practice - 16/07/22

, Arianna F. Yanes, MD b, Brian Cheng, BS c, Jeremy R. Etzkorn, MD, MS b, Christopher J. Miller, MD b, Thuzar M. Shin, MD, PhD b, Joseph F. Sobanko, MD b, H. William Higgins, MD, MBE b, Stacy L. McMurray, MD b, Joanna L. Walker, MD b, Cerrene N. Giordano, MD b| Funding sources: Dr Giordano is supported by the McCabe Fund Fellow Award from the Perelman School of Medicine. Dr Etzkorn is supported by a Dermatology Foundation Career Development Award in Dermatologic Surgery. Dr Shin is supported by Regeneron Pharmaceuticals. No funding sources were used toward this research and manuscript. The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. |
|
| IRB approval status: Reviewed and exempted by the University of Pennsylvania IRB. |
Vol 87 - N° 2
P. 492-494 - août 2022 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
